AtaCor Medical raises $75M to fund pivotal U.S. trial of extravascular ICD system
- bancheta6
- Oct 8
- 1 min read
San Clemente, CA, October 6, 2025 (PRNewswire) -- AtaCor Medical secured $75 million to support its U.S. FDA pivotal study of the Atala™ extravascular implantable cardioverter-defibrillator (EV-ICD) system, designed to deliver full defibrillation and antitachycardia therapies without hardware inside the heart or vasculature. The system uses a parasternal lead and subcutaneous pulse generator, offering a less invasive approach while maintaining therapy efficacy. CEO Rick Sanghera said the financing positions AtaCor to meet the growing need for safer, effective ICD options and advance the device toward clinical use.
Read full article here.
Comments